These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312 [TBL] [Abstract][Full Text] [Related]
3. Functional screening of pharmacological chaperones via restoration of enzyme activity upon denaturation. Shanmuganathan M; Britz-McKibbin P Biochemistry; 2012 Oct; 51(39):7651-3. PubMed ID: 22970758 [TBL] [Abstract][Full Text] [Related]
15. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154 [TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Yang C; Rahimpour S; Lu J; Pacak K; Ikejiri B; Brady RO; Zhuang Z Proc Natl Acad Sci U S A; 2013 Jan; 110(3):966-71. PubMed ID: 23277556 [TBL] [Abstract][Full Text] [Related]
17. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease. Trapero A; González-Bulnes P; Butters TD; Llebaria A J Med Chem; 2012 May; 55(9):4479-88. PubMed ID: 22512696 [TBL] [Abstract][Full Text] [Related]
18. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. Yu Z; Sawkar AR; Whalen LJ; Wong CH; Kelly JW J Med Chem; 2007 Jan; 50(1):94-100. PubMed ID: 17201413 [TBL] [Abstract][Full Text] [Related]
19. Novel compounds that reverse the disease phenotype in Type 2 Gaucher disease patient-derived cells. Childers W; Fan R; Martinez R; Colussi DJ; Melenski E; Liu Y; Gordon J; Abou-Gharbia M; Jacobson MA Bioorg Med Chem Lett; 2020 Jan; 30(2):126806. PubMed ID: 31757667 [TBL] [Abstract][Full Text] [Related]